BACKGROUND: Chronic renal failure is a progressive and irreversible loss of kidney function, and the hemodialysis (HD) is one of the most common modalities in this regard. Oxidative stresses [like interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α)] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients; meanwhile, antioxidants like alpha lipoic acid (ALA) may reduce the oxidative stress markers and the levels of inflammatory cytokines, so can improve of the patient's quality of life. METHODS: In this randomized clinical trial study, 60 HD patients were randomly categorized in two case and control groups. Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks, and the control group received placebo capsules daily. The serum level of IL-8and TNF-α was measured in both groups before and after the intervention. RESULTS: There were no significant differences in age, gender, duration of dialysis, and causative factor for dialysis between both groups (P > 0.05). The mean of IL-8and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61, respectively; the difference between both groups was not statistically significant (P > 0.05). CONCLUSION: Based on the better feeling and other beneficial effects of ALA were found in our study; we can conclude that it is a beneficial and recommended supplement, especially, for diabetic and dialysis patients.
RCT Entities:
BACKGROUND:Chronic renal failure is a progressive and irreversible loss of kidney function, and the hemodialysis (HD) is one of the most common modalities in this regard. Oxidative stresses [like interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α)] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients; meanwhile, antioxidants like alpha lipoic acid (ALA) may reduce the oxidative stress markers and the levels of inflammatory cytokines, so can improve of the patient's quality of life. METHODS: In this randomized clinical trial study, 60 HDpatients were randomly categorized in two case and control groups. Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks, and the control group received placebo capsules daily. The serum level of IL-8 and TNF-α was measured in both groups before and after the intervention. RESULTS: There were no significant differences in age, gender, duration of dialysis, and causative factor for dialysis between both groups (P > 0.05). The mean of IL-8 and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61, respectively; the difference between both groups was not statistically significant (P > 0.05). CONCLUSION: Based on the better feeling and other beneficial effects of ALA were found in our study; we can conclude that it is a beneficial and recommended supplement, especially, for diabetic and dialysis patients.
Authors: Luis F Ramos; Jane Kane; Ellen McMonagle; Phuong Le; Pingsheng Wu; Ayumi Shintani; Talat Alp Ikizler; Jonathan Himmelfarb Journal: J Ren Nutr Date: 2010-12-24 Impact factor: 3.655
Authors: I Ceballos-Picot; V Witko-Sarsat; M Merad-Boudia; A T Nguyen; M Thévenin; M C Jaudon; J Zingraff; C Verger; P Jungers; B Descamps-Latscha Journal: Free Radic Biol Med Date: 1996 Impact factor: 7.376
Authors: P S van Dam; B S van Asbeck; J F Van Oirschot; G J Biessels; F P Hamers; J J Marx Journal: Eur J Clin Invest Date: 2001-05 Impact factor: 4.686
Authors: D Ziegler; M Hanefeld; K J Ruhnau; H Hasche; M Lobisch; K Schütte; G Kerum; R Malessa Journal: Diabetes Care Date: 1999-08 Impact factor: 19.112
Authors: Carmelita G Frondoza; Lowella V Fortuno; Mark W Grzanna; Stacy L Ownby; Angela Y Au; Ann M Rashmir-Raven Journal: Cartilage Date: 2017-01-10 Impact factor: 4.634